WALTHAM, Mass., June 1 /PRNewswire/ -- IntrinsiQ, LLC, a leader in medical oncology care software, unveiled its IntelliCharge module for IntelliDose(R), the oncology clinical information solution developed to automate the complex process of chemotherapy care. The announcement was made in conjunction with the opening of the 43rd annual American Society of Clinical Oncology (ASCO) meeting today in Chicago, IL. IntelliCharge improves control and billing of costly chemotherapy drugs through automatic and precise calculation of chemotherapy encounter charges, all taken directly from detailed nursing notes. Drug and professional services codes are seamlessly passed to the billing system via an HL7 interface.
Based on feedback from thousands of oncology practices, of all types and sizes, the newest enhancements to IntelliDose continue to provide the highest level of efficiency, safety, and integration to meet the diverse needs of the oncology market. By linking IntelliDose to a Practice Management or billing system, paperless chemotherapy charge posting and billing can be achieved. IntelliCharge calculates the relevant CPT and J codes directly from the documented nurse note for each chemotherapy encounter. All information is summarized in a detailed billing report and data is easily transferred via an HL7 interface. Inaccurate and incomplete super bills are gone. Missed or lost charges are minimized.
“We are constantly updating and refining IntelliDose to meet the needs of the busy oncology practice. Our clients have continued to emphasize the importance of cost monitoring and control. This is paramount in today’s climate of ever changing reimbursement rules and greater restrictions. Providing automated charge calculation directly tied to our nurse charting module provides a seamless, easy-to-use solution that efficiently integrates with the practice billing system. Most importantly this meets our customer market needs,” commented Bill Wisotzkey, General Manager, IntelliDose.
IntelliDose automates the delivery of cancer care. A strong focus on chemotherapy planning and management provides many safeguards against dosing errors and other patient safety concerns. The system reduces risks, increases efficiency, and tracks therapy and associated costs. Specific documentation tools for both the physician and nurse are included to ensure the patient record is accurate and complete. IntelliDose is a key resource for the oncologist, chemotherapy nurse, pharmacist and practice administrator. Only IntelliDose supports end-to-end care of cancer patients.
“We have seen a tremendous improvement in efficiency, safety and integration from the beginning with IntelliDose,” said Stuart J. Wong, M. D., Assistant Professor of Medicine, Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin. “Refinements and enhancements to the system will help us continue to cut costs, provide the highest quality of care and ensure the highest degree of patient safety.”
About IntrinsiQ, LLC
IntrinsiQ is the premier source for US oncology data and analysis. IntrinsiQ’s market leading software application, IntelliDose(R), captures the treatment decisions and details of over 14,000 patients a month, creating an unrivaled database of accurate, detailed and timely information about the medical oncology care process. This database is the foundation of products and services that are designed to uniquely address the business issues and decisions to the pharmaceutical product manager, market researcher and financial analyst. For more information, please visit http://www.intrinsiq.com .
IntrinsiQ, LLC
CONTACT: Karen Barzilay, +1-508-794-1039, cell, +1-508-735-8584,karenbarzilay@comcast.net, or Kathleen Van Gorden, +1-401-454-7591, cell,+1-401-480-1840, kathleenv@kvgcom.com, both for IntrinsiQ, LLC
Web site: http://www.intrinsiq.com/
